MED — Medifast, Inc. · 2026-09-07 · Verdict: WATCH · Conviction 3
Price $12.63 (screen row close, screen dated 2026-09-06; no live quotes available) · Mkt cap $141M · EV about negative $29M (cash and investments $169.8M, no debt) · EV/EBIT n/m (LTM operating loss $19.5M) · FCF yield ~2.8% on market cap · Net cash $169.8M · ADV $1.4M Sources read: 10-K 2026-02-17 (Items 1, 1A, 7), 10-Q 2026-08-03, DEF 14A 2026-04-06, 8-Ks of 2026-03-20, 05-04, 05-26, 06-01, 07-17, 08-03, Form 4s (12 of 13 in trailing 12 months). No transcript or prepared remarks were filed as an exhibit, so section 5 rests on written guidance versus reported results.
1. What the business actually does
Medifast sells meal replacements and a coach-led weight and metabolic health program, rebranded from OPTAVIA to Trilivy in July 2026 (8-K 2026-07-17). Product sales were 96.4% of 2025 revenue and one segment carries all of it. Sales are direct to consumer through independent contractor coaches, about 90% of whom were clients first and who never hold inventory; roughly 40% of unit volume is made at a single owned plant in Owings Mills, Maryland (10-K 2025, Items 1, 1A and 7). The business is one number: active earning coaches times revenue per coach.
2. Why it is mispriced, and the honest answer
There is no dislocation. The screen was wrong in the company's favour, which is a different thing: it read $71.9M of cash, flagged long-term debt as untagged, and priced enterprise value at $69.3M. The real balance sheet at 30 June 2026 holds $71.9M of cash plus $97.9M of investments, $169.8M in total, against $64.0M of liabilities that are only payables and leases, with no debt (8-K 2026-08-03). You pay $141M for $169.8M of liquid assets and $196.4M of all-tangible book, so enterprise value is negative and the plant, brand and coach network come attached at less than nothing.
But nothing forces anyone to sell. The stock is 13.3% below its 52-week high after rising 17.3% in six months on $1.4M of daily volume (screen row, 2026-09-06), and the collapse is old news: $100 invested at end-2020 was worth $6 at end-2025 against $116 for the S&P 600 Consumer Staples, on revenue that fell from $1,526M to $386M (DEF 14A 2026-04-06). The discount is not a mispricing anyone is trapped in. It is the market's judgment that the cash gets consumed, which caps this at WATCH.
3. Unit economics and growth
Revenue fell 36.0% to $385.8M in 2025 as active earning coaches fell 40.6% to 16,100, a count declining year over year since Q1 2023 (10-K 2025, Item 7). It has not stopped: 14,000 coaches in Q1 2026 and 11,700 in Q2, down 48.7% (8-Ks 2026-05-04, 2026-08-03). H1 2026 revenue fell 31.1% to $152.4M with a $7.6M operating loss against $2.3M (10-Q Q2 2026).
Management's offset is revenue per coach, up 41.0% to $6,529 in Q2, attributed to "prioritizing productive coaches and efficient coach network structures" (8-K 2026-08-03). That phrasing matters: culling low producers raises the average without adding a dollar of revenue. The offset has held exactly once, Q1 at $76.0M and Q2 at $76.4M, and the 10-Q says coach counts should keep declining in 2026.
Gross margin slid from 71.3% in 2025 to 69.9% in Q2 on fixed-cost absorption, but the cost base is the real problem. Q2 carried $57.7M of SG&A on $53.4M of gross profit, and coach compensation fell $12.6M against a $29.2M revenue decline, so about 43% of lost revenue comes back automatically and 57% does not. On that arithmetic breakeven sits near $350M of annual revenue, against $270M to $300M guided and falling.
4. Balance sheet and capital allocation
Cash and investments went $167.3M to $169.8M in six months while the company lost $5.2M, so the pile is stable for now, with no debt and no revolver since the Citibank facility was terminated undrawn in October 2024 (10-Q Q2 2026; 10-K 2025, Item 7). Capex was $5.6M in 2025.
What management does with the cash is the uncomfortable part. The dividend was discontinued in December 2023, and no repurchase program appears in the 10-K liquidity section, the proxy, or either 2026 earnings release, at 0.72x tangible book. Meanwhile lease obligations rose from $10.7M to $27.6M in six months on a new headquarters and a Havre de Grace extension, adding fixed cost while revenue fell a third (8-K 2026-08-03).
Insider buying is real and is one holder. Steamboat Capital signed a cooperation agreement on 19 March 2026 seating Parsa Kiai and Jeff Rose as two directors stood down, with a standstill through the 2027 annual meeting (8-K 2026-03-20). Kiai then bought 119,966 shares for about $1.42M between 19 and 26 August at $11.60 to $12.26, taking his controlled position to 707,492 shares, with zero open-market sales across 27 Form 4 rows. Caveat: those client shares are pledged to prime brokers for margin borrowing (DEF 14A 2026-04-06, footnote 3).
5. Management: said versus did
Dan Chard handed the CEO role to Nick Johnson on 1 June 2026, and the Chief Legal Officer resigned on 29 May with one month of base salary (8-Ks 2026-05-26, 2026-06-01). The 2025 bonus plan targeted $11.0M of Adjusted EBITDA at maximum, which is the honest scale of the ambition (DEF 14A 2026-04-06). They delivered one real improvement: on 4 May the FY26 guide was revenue $270M to $300M with a $1.55 to $2.75 loss per share; on 3 August revenue was held and the loss guide cut to $0.25 to $1.75, after Q2 lost $0.28 against a $0.50 to $1.00 guide.
What does not yet check out is "we believe we are on track to return to profitability in the fourth quarter" (Johnson, 8-K 2026-08-03). At midpoints, full year $285M less H1 $152.4M less Q3 $70M leaves about $62.6M for Q4, down 18% from Q2, and the per-share guide implies a Q4 between $0.37 of profit and $0.63 of loss, midpoint roughly a $0.13 loss. The Q3 range also explicitly excludes one-time Catalyst costs, which if carried in the full-year figure makes reported Q4 worse. Profit at $62.6M of revenue needs $9M to $10M of quarterly fixed cost out of Catalyst, a program described only as "facility rationalization, AI-related efficiencies and other means" with no dollar target attached.
6. Valuation
Bear (45%): coaches keep falling 30% to 40% a year, Catalyst under-delivers, revenue goes $285M to $210M to $160M, and $55M to $60M of cumulative burn and restructuring leaves about $110M of cash and a worthless business. About $9.80. Base (40%): Catalyst delivers half of what is needed, revenue troughs near $240M in 2027 at roughly breakeven, cash holds near $155M, plant and brand worth $30M. About $16.50. Bull (15%): Trilivy and the new compensation plan stop the coach bleed in 2027, revenue recovers to $300M by 2029 at a 6% margin, $18M of EBIT at 10x plus $150M of cash. About $29.50. Probability-weighted about $15.45, or 22% above price, on a very wide distribution.
Reverse DCF: at $12.63 the market pays $141.2M for $169.8M of cash and investments plus $28.0M of net property with no debt, so the price implies the operating business is worth about negative $29M, that Trilivy consumes roughly $29M of the cash pile in present value and is then worth zero.
7. Catalysts and timeline
The Q3 print in early November 2026 is the first read on Catalyst savings in SG&A against a $60M to $80M revenue guide. The Q4 print, likely February 2027, tests the profitability claim and brings the first FY2027 guide. The Trilivy Fueling rollout and the new coach compensation plan both landed in Q3 2026, so their effect on coach count shows in those same two quarters. The Steamboat standstill lapses around May 2027, the earliest date anything can be forced.
8. Kill criteria
- Cash and investments below $150M at any quarter end, more than $20M of net burn from the $169.8M reported at 30 June 2026.
- Q4 2026 fails to produce positive operating income, or FY2026 loss per share lands in the lower half of the $0.25 to $1.75 guide.
- Revenue per active earning coach falls year over year in any quarter, meaning the productivity offset holding revenue flat has broken.
- Kiai or Rose leaves the board, or the Steamboat-controlled position falls below 500,000 shares.
Risks outside those tests: management names GLP-1 adoption as the cause in every filing, so the decline is structural rather than cyclical, and the full valuation allowance against deferred tax assets is management's own statement that future profits are not more likely than not (10-K 2025, Item 7).
9. Verdict and summary
WATCH, conviction 3. Medifast is a genuine sub-liquidation-value situation the screen understated by $97.9M: $141M of market value against $169.8M of cash and investments, no debt, $196.4M of all-tangible book, and an activist holding about 6% who bought $1.42M of stock in the open market at up to $12.26 three weeks after the Q2 print. What stops it being an idea is that nothing forces the discount to close while the asset melts. The stock sits 13% below its 52-week high after rising 17% in six months, so there is no dislocation to underwrite; active earning coaches are down 48.7% year over year to 11,700 with management stating in writing that they will keep falling; revenue is flat only because culling low producers lifted revenue per coach 41%; and the Q2 cost base needs roughly $350M of annual revenue to break even against $270M to $300M guided. Management's own guidance midpoint implies a fourth quarter losing about $0.13 a share rather than the promised return to profitability, and the Catalyst program that would close that gap carries no dollar target. The board has never authorised a buyback at 0.72x tangible book, added $17M of lease obligations while revenue fell a third, and cannot be pushed by Steamboat until the standstill lapses around May 2027. November and February settle it: if Catalyst shows up in SG&A and the coach count flattens, the negative enterprise value becomes an idea; if cash drains toward $150M it is a value trap with a clock on it.
Research for discussion, not investment advice. Positions and sizing are the reader's decision.